Treatment switch improves CRT in some patients
Click Here to Manage Email Alerts
Central retinal thickness was reduced in some patients with DME or wet AMD after a change in anti-VEGF treatment, according to a poster presented at the virtual Association for Research in Vision and Ophthalmology meeting.
Sohel Somani, MD, FRCSC, and colleagues evaluated treatment outcomes in patients with neovascular age-related macular edema (AMD) and diabetic macular edema (DME) who were switched from Eylea (aflibercept, Regeneron) to ranibizumab pre-filled syringes (Genentech).
The PRECISE study, an ongoing, prospective, observational real-world study, enrolled 177 patients with neovascular AMD and 35 patients with DME by December 2019; planned total enrollment is 396 patients from 15 clinical sites across Canada.
Persistent fluid was identified as the primary reason for switching treatment in 65.5% of patients with neovascular AMD and 80% of patients with DME. Somani reported interim results for patients with data available at 90 days of follow-up after the treatment switch.
“There was a subtle but not statistically significant difference in the reduction of central retinal thickness at day 90 in the wet AMD group, and there was a statistically significant decrease in central retinal thickness in the diabetic macular edema group,” Somani said.
That is, of 72 patients with neovascular AMD followed up at 90 days, mean CRT decreased from 288.2 µm at baseline to 278.6 µm. In 17 patients with DME, mean CRT decreased from 377.5 µm to 348.9 µm (P = .026).
Mean CRT in the 177 patients with neovascular AMD was 287 µm at baseline and 357.4 µm in the patients with DME.
In both groups, there was no statistically significant change in visual acuity from baseline to day 90.
“Our final results will perhaps shed more light on outcomes and reasons for switching from aflibercept to ranibizumab, and perhaps further understanding in the treatment of both of these very common conditions,” Somani said.
Collapse
Somani S, et al. Treatment switch from aflibercept to ranibizumab pre-filled syringe in Canadian nAMD and DME patients in a real-world setting: The PRECISE study. Presented at: Association for Research in Vision and Ophthalmology annual meeting; June 12, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts